Prelude Therapeutics Founder Acquires 28% More Stock [Yahoo! Finance]
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: Yahoo! Finance
That's a very solid buy in our book, and increased their holding by a noteworthy 28%. In fact, the recent purchase by Krishna Vaddi was the biggest purchase of Prelude Therapeutics shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of US$0.80. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices. While Prelude Therapeutics insiders bought shares during the last year, they didn't sell. The average buy price was around US$0.77. These transactions show that insiders have confidence to invest their own money in the stock, albeit at slightly below the recent price. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) ProgramsGlobeNewswire
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLDPR Newswire
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
PRLD
Earnings
- 11/12/25 - Beat
PRLD
Analyst Actions
- 9/23/25 - HC Wainwright
PRLD
Sec Filings
- 12/17/25 - Form EFFECT
- 12/10/25 - Form S-3
- 11/12/25 - Form 10-Q
- PRLD's page on the SEC website